Novartis meningitis vax promising in PhIII

Novartis' meningitis B vaccine, 4CMenB, has turned in promising late-stage data with "an acceptable" safety profile. After testing the drug in more than 3,600 infants, Novartis reported that its researchers tracked a "robust" immune response. A European app is expected by the end of this year. Story

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.